Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352009 | 0.84 | ACHE (0.47) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL29365032 | 0.84 | ACHE (0.47) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL19836626 | 0.83 | ALDH1A1 (0.54) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL30702212 | 0.79 | MAPT (0.56) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3948845 | 0.79 | MAPT (0.56) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL5311960 | 0.77 | KMT2A (0.55) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL856747 | 0.77 | ACHE (0.56) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL28207369 | 0.77 | MAPT (0.51) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL23618751 | 0.76 | MAPT (0.70) | KDM4EMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL9257883 | 0.75 | CYP19A1 (0.42) | KDM4EMEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085332-A1 | ANTIBODY-BOUND METAL-ORGANIC FRAMEWORK AND ANTICANCER COMPOSITION COMPRISING SAME | 울산과학기술원 | 2024-04-25 | — | — | WO | claimed |
| US-20260104418-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250333501-A1 | CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER | UNIV CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250282870-A1 | CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER | BIOENTRE LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3458477-B1 | ANTI-FACTOR IX PADUA ANTIBODIES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-12345709-B2 | CLAUDIN18 antibodies and methods of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-01 | — | — | US | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4527408-A2 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | The Regents of the University of California (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119592693-A | Application of Circ2977 as colorectal cancer diagnosis marker and treatment target | 重庆医科大学国际体外诊断研究院 | 2025-03-11 | — | — | CN | disclosed |
| WO-2022125967-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | ERASCA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220177583-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| US-20220160872-A1 | Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-05-26 | — | — | US | disclosed |
| US-20220162299-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
| EP-3999548-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of the University of California (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022081773-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022076529-A1 | METHODS FOR X CHROMOSOME REACTIVATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3956663-A1 | A METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-23 | — | — | EP | disclosed |
| EP-3952841-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113981243-A | Method for extracting and separating lithium and alkaline earth metal from salt lake brine with high sodium-lithium ratio | 中国科学院青海盐湖研究所 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260104418-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | EPCAM, IGSF11, EPB41L2 | KDM4E 1155/4885MEN1 2600/4885MAPT 1819/4885 |
| US-20220162299-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | EPCAM, LY96, CD2BP2 | KDM4E 3852/4885MEN1 4141/4885MAPT 2024/4885 |
| US-20220177583-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | EPCAM, CD2BP2, LY96 | KDM4E 4130/4885MEN1 3768/4885MAPT 2576/4885 |
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | CD2BP2, CD2, DBNL | KDM4E 3691/4885MEN1 3223/4885MAPT 2266/4885 |
| US-12345709-B2 | CLAUDIN18 antibodies and methods of treating cancer | EPCAM, ICAM1, VCAM1 | KDM4E 4279/4885MEN1 2014/4885MAPT 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.